Clinical Impact

Techulon is advancing a new generation of therapeutics with broad application based on technology that is highly selective of disease targets. This results in more effective drugs that exhibit fewer side effects to patients. The company has demonstrated the benefits of this approach in a series of animal safety and efficacy studies and is now poised to translate these findings into clinical applications. Management believes this new approach provides a sustainable competitive advantage for high revenue growth potential and long-term value.

The company intends to apply this technology first to a family of treatments for ‘superbugs’ (bacteria that have become resistant to many or all known antibiotics) based on a proven approach that selectively kills the infection without leaving the patient at risk for dangerous side effects such as organ toxicity. Over $30B in cost is incurred in our healthcare system annually due to these infections. Techulon’s lead superbug candidate is directed at the $2b market for methicillin-resistant staphylococcus aureus (MRSA).


Drug Resistant Bacteria — A Mounting Concern

Drug resistant bacteria pose a serious threat to clinical settings including hospitals, clinical outpatient care facilities, and military operating areas subjected to the needs of burn victims and wound care.  The World Health Organization recently released a report on the global public health threat of antibiotic resistant infections.

Contrary to the specificity of Techulon’s approach, traditional antibiotics flood the patient with a broad spectrum killing agent and, while defeating the target, it adversely affects other important bacteria in the patients body, disrupting normal functions and creating the need for supplemental treatments to rebalance the physiological order.

Drug resistant infections cause over $30B in healthcare cost annually and are responsible for 100,000 deaths per year. The overall market for therapeutics ranging across drug resistant bacteria has been estimated in excess of $10B.

DARPA has provided Techulon with $1.9M to develop drugs for wounded soldiers who are susceptible to infections.



Techulon’s lead candidate for therapeutic application is directed at the $2b market for methicillin-resistant staphylococcus aureus (MRSA). The CDC has rated this bacterial infection at a ‘Serious’ Hazard level and is encouraging qualified entrants to submit leading candidates for evaluation.

Gram-Negative Infections

Techulon is also building a pipeline of therapies targeted at other families of bacteria and expects to have additional candidates rapidly due to the speed and flexibility of our platform approach.
The above images are the
property of the CDC.